New research from UMCG cardiologists suggests a low-dose, inexpensive heart medication can significantly reduce hospital admissions for patients with heart failure.

Three studies led by cardiologists at the University Medical Center Groningen (UMCG) indicate that a low dose of the medication digoxin may help heart failure patients avoid hospitalization. The findings suggest that adding this inexpensive drug to standard treatment regimens could improve outcomes and potentially influence future clinical guidelines.

Study Findings and Methodology

Researchers analyzed data from 1,000 heart failure patients across 43 centers in the Netherlands, comparing those who received a low dose of digoxin alongside standard care against those who received a placebo. While initial results showed a 19% reduction in cardiovascular deaths and worsening heart failure, this specific figure did not reach statistical significance on its own. However, a meta-analysis combining these findings with two earlier studies revealed a statistically significant benefit, including a 25% average reduction in heart failure-related hospital admissions.

Clinical Impact and Medication Costs

Digoxin, a medication used for centuries, costs less than ten cents per day, making it significantly cheaper than many modern heart failure treatments. Currently, only about 15% of heart failure patients are prescribed the drug, as its use has declined over the last three decades. Researchers noted that at low doses, digoxin primarily functions by reducing harmful compensatory responses, such as suppressing stress hormones like adrenaline, rather than forcing the heart muscle to contract more forcefully as higher doses did in the past.

Research Funding and Observations

The research was supported by 3 million euros in funding from the Hartstichting in collaboration with ZonMw. In a follow-up observation of approximately 600 participants, researchers noted that patients who stopped taking digoxin experienced more health complications in the first six weeks than those who had never taken the drug. While the team noted this does not directly prove efficacy, they described the timing and scale of the effect as surprising.